DocDollars

Biocryst Pharmaceuticals, Inc.

NC · United States · Reporting entity ID 100000136528

Total reported 2019–2025
$15.8M
#376 of 2,960 reporting companies — 0% of all reported industry payments
$2.78M in general payments across 2,434 records, plus $13.1M in research funding across 852 records.

How it breaks down

General payments $2,781,251
Research funding $13,060,907

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Biocryst Pharmaceuticals, Inc. reported $15.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #376 of 2,960 reporting companies. 82% of that was research funding and 18% general payments such as consulting, speaking, food and travel. 2,434 general payment records and 852 research records were filed.

Common questions about Biocryst Pharmaceuticals, Inc.

How much has Biocryst Pharmaceuticals, Inc. paid US doctors?

Biocryst Pharmaceuticals, Inc. reported $15,842,158 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,781,251 in general payments, $13,060,907 in research funding.

How does Biocryst Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #376 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Biocryst Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.